Innova&on Trends in Immuno-Oncology - Uncovering the state of innova0on in immuno-oncology - May 16 2018
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Innova&on Trends in Immuno-Oncology Uncovering the state of innova0on in immuno-oncology Ane7e Breindl, PhD, Senior Science Editor, BioWorld Bob Stembridge, Senior IP Analyst, Clarivate Analy:cs May 16, 2018
Immuno-oncology: Cancer’s Penicillin Moment AneAe Breindl Senior Science Editor BioWorld May, 2018
3
Immuno-oncology: current landscape
• CAR T cells:
¨ Kymriah and Yescarta approved in 2017
¨ So far, very small numbers of pa:ents
• Checkpoint blockers, which increase T cell ac:vity, are in wider clinical use
¨ CTLA-4 blocker (increases T cell ac:va:on)
Yervoy
¨ PD-1 or PD-L1 blocker (prevents T cells from being shut off once ac:vated)
Five approved
• Provenge
4 Genentech’s vice president of immuno-oncology has called the development of checkpoint blockers “cancer’s penicillin moment” That analogy applies to their cura:ve effects, but also to their limits awash in. “I just don’t know if we’re using it correctly.”
5
Checkpoint blockade – future direc&ons
• Key goal: increase the response rate
¨ Conver:ng unresponsive (“cold”) into “hot” tumors
Source: Chen & Mellman, Immunity 2013; Chen &
Mellman, Nature 2017
6
Checkpoint blockade – future direc&ons
• Key goal: increase the response rate
¨ Combina:on therapies
7
Checkpoint blockade – future direc&ons
• Key goal: increase the response rate
¨ Biomarkers
-Best current biomarker is high muta:onal burden
This is thought to be because high muta:onal burden translates into high neoan:gen load
BUT
All it takes is one
8
CAR T cells
• So far, CAR T cells have found clinical success only in B cell malignancies, because B cells have very
specific surface markers and you can live well without an:body-producing cells
• Finding an:gens on solid tumors that can be targeted with sufficient specificity has not been
successful yet
9
CAR T cells – future direc&ons
• Key goal: expand indica:ons/eligible popula:ons
¨ “Logic ga:ng” to allow T cells to respond to signal combina:ons
¨ Locoregional delivery can also be a solu:on for certain tumor types
10
CAR T cells– future direc&ons
q Key goal: increase response rate – “armored CARs”
From Avanzi et al., Cell Reports, May 15, 2018Immuno-oncology patent landscape analysis Bob Stembridge Senior IP Analyst May, 2018
12 Agenda Trends in oncology dealmaking 01 Immuno-oncology patent landscape 02 Major players by target/therapy 03 Iden:fying poten:al partners through cita:on analysis 04 Poriolio comparison of major licensing deal partners 05
13
Trends in oncology dealmaking
• Oncology is currently the leading area for
dealmaking, driven by immuno-oncology
• 32 of the 35 mul:billion-dollar oncology licensing
deals of the last five years are focused on immuno-
oncology
• “Trends in oncology dealmaking” by Jamie Munro
and Helen Dowden of Clarivate Analy:cs explores
the recent trends in oncology deals
hAps://biopharmadealmakers.nature.com/users/9880-biopharma-
dealmakers/posts/30794-trends-in-oncology-dealmaking
Source: Clarivate Analy0cs Integrity Targets & Pathways
overview of PD-L1/PD-1 immune checkpoint inhibi0on14
Oncology con&nues to dominate the dealmaking landscape
The top 50 pharmaceu:cal companies (ranked by 2016 revenues)
Source: Clarivate Analy0cs Cortellis15 Licensing, joint venture and research-only oncology deals by volume and value from 2013 to 2017
16
Oncology licensing, joint venture and research-only deals valued at more than $1 billion from 2013 to 2017
Source: Clarivate Analy0cs Cortellis17
Oncology licensing, joint venture and research-only deals valued at more than $1 billion from 2013 to 2017
Source: Clarivate Analy0cs CortellisThe State of Innova&on Uncovering key areas and trends within the immuno- oncology patent landscape
19
Immuno-oncology patent landscape
Source: Cortellis, Derwent Innova0on, Themescape20
Immuno-oncology patents 2008-2018
900
800
700
CTLA-4
600
PD-1
DWPI families
500 PD-L1
Ox40
400
TIM3
300 LAG3
CAR T-Cell
200
100
0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Source: Cortellis, Derwent Innova0onWho are the players? Major players by target/ therapy area
22
Checkpoint inhibitors
CTLA-4 PD-1 PD-L1
BMS 60
BMS 88 ROCHE/GENENTECH 57
NOVARTIS 40 NOVARTIS 57 DANA FARBER CANCER INST 43
DANA FARBER CANCER INST 38 UNIV PENNSYLVANIA 56 BMS 36
SLOAN KETTERING INST 26 ROCHE/GENENTECH 55 NOVARTIS 36
ABBVIE 25 DANA FARBER CANCER INST 54 MERCK & CO 28
IMMUNOMEDICS 23 MERCK & CO 34 MEDIMMUNE 22
PFIZER 22 SLOAN KETTERING INST 26 UNIV PENNSYLVANIA 21
UNIV CALIFORNIA 22 UNIV TEXAS SYSTEM 25 IMMUNOMEDICS 19
US DEPT HEALTH 21 IMMUNOMEDICS 23 HARVARD COLLEGE 16
ROCHE/GENENTECH 20 UNIV JOHNS HOPKINS 22 SLOAN KETTERING INST 15
0 50 100 0 50 100
0 50 100
DWPI families DWPI families DWPI families
Source: DWPI and full text patents collec0on
on Derwent Innova0on23
Checkpoint inhibitors
Ox40 TIM3 LAG3
NOVARTIS 50 NOVARTIS 33 NOVARTIS 32
UNIV PENNSYLVANIA 49 DANA FARBER CANCER INST 31 DANA FARBER CANCER INST 27
ROCHE/GENENTECH 20 BRIGHAM & WOMENS HOSPITAL 16 SLOAN KETTERING INST 17
DOMANTIS 18 SLOAN KETTERING INST 14 BMS 13
DANA FARBER CANCER INST 17 UNIV LELAND STANFORD JUNIOR 12 UNIV PENNSYLVANIA 12
SLOAN KETTERING INST 16 UNIV PENNSYLVANIA 11 INSERM 11
MERCK & CO 10 ROCHE/GENENTECH 10 HARVARD COLLEGE 10
FRED HUTCHINSON CANCER 10 US DEPT HEALTH 9 US DEPT HEALTH 10
UNIV JOHNS HOPKINS 9 AGENUS 9 ROCHE/GENENTECH 9
ABBVIE 9 MERCK & CO 8 FRED HUTCHINSON CANCER RES 9
0 100 0 50 0 50
DWPI families DWPI families DWPI families
Source: DWPI and full text patents collec0on
on Derwent Innova0on24 Chimeric An&gen Receptor T-cell (CAR T-cell) therapy
25 Chimeric An&gen Receptor T-cell (CAR T-cell) therapy
Where is the opportunity? Iden:fying poten:al partners through cita:on analysis
27 Themescape map of CAR T-Cell therapy patent landscape
28
University of Pennsylvania: USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER
Organiza&ons ci&ng
WO2012079000
UNIV PENNSYLVANIA 46
NOVARTIS 28
US DEPT HEALTH 16
CELLECTIS 16
BROAD INST 7
MIT 6
ANTHROGENESIS 6
UNIV CALIFORNIA 5
UNIV TEXAS SYSTEM 5
CEDARS SINAI MEDICAL 5
0 10 20 30 40 50
Source: DWPI and full text patents collec0on
on Derwent Innova0onHow good is the fit? A poriolio comparison of major licensing deal partners
30 Merck & Co and AstraZeneca PD-1 patent pordolios
31 Merck & Co and AstraZeneca PD-1 patent pordolios
32 Pfizer and Cellec&s CAR T-cell therapy patent pordolios
33
Summary
• 32 of the 35 mul:billion-dollar oncology licensing deals of the last five years are focused on immuno-
oncology
• The scien:fic founda:ons of immuno-oncology are rapidly transla:ng to IP rights to protect and
commercialise the most promising avenues
• Patent growth in checkpoint inhibitors and CAR T-Cell therapy in par:cular has been explosive over
the past three years and con:nues unabated
• Forward cita:on analysis of patents can indicate I-O patents 2008-2018 (projected)
poten:al collabora:on partners and/or licensees 2500 CTLA-4
• Poriolio mapping analysis can indicate areas of 2000
PD-1
overlap/complementarity of technology 1500
PD-L1
1000
Ox40
500
0 TIM3
2008
2009
2011
2015
2017
2018
2010
2012
2013
2014
2016
LAG334 Q&A
Thank you! Interested in learning more about Derwent? Request a free trial at clarivate.com/products/derwent
You can also read
